Over 12 months, Viking Therapeutics, Inc. saw more selling than buying from its insiders — purchases of about $150,000 against sales of $22.3 million.
Biggest single buyer: Aubuchon Neil William, Executive Officer, with roughly $150,000.
Big money check: 434 institutions held VKTX as of Q2 2026, and more funds bought than sold. Zooming out by quarter: Last full quarter: net selling by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Lian Brian | CEO | Sell | 148,517 | $33.32 | $4.9M | SEC |
| Jul 29, 2026 | ZANTE GREG | CFO | Sell | 21,217 | $33.47 | $710K | SEC |
| Jul 29, 2026 | Mancini Marianna | COO | Sell | 18,217 | $33.47 | $610K | SEC |
| Mar 10, 2026 | Aubuchon Neil William | Executive Officer | Buy | 4,475 | $33.50 | $150K | SEC |
| Jan 5, 2026 | ZANTE GREG | CFO | Sell | 13,900 | $33.38 | $464K | SEC |
| Jan 5, 2026 | ZANTE GREG | CFO | Sell | 1,500 | $32.09 | $48K | SEC |
| Jan 5, 2026 | Mancini Marianna | COO | Sell | 31,961 | $32.29 | $1.0M | SEC |
| Jan 5, 2026 | Mancini Marianna | COO | Sell | 13,600 | $33.37 | $454K | SEC |
| Jan 5, 2026 | Mancini Marianna | COO | Sell | 10,500 | $34.22 | $359K | SEC |
| Jan 5, 2026 | Mancini Marianna | COO | Sell | 1,600 | $35.07 | $56K | SEC |
| Jan 5, 2026 | Lian Brian | CEO | Sell | 6,400 | $35.07 | $224K | SEC |
| Jan 5, 2026 | Lian Brian | CEO | Sell | 53,279 | $33.38 | $1.8M | SEC |
| Jan 5, 2026 | Lian Brian | CEO | Sell | 41,276 | $34.22 | $1.4M | SEC |
| Jan 5, 2026 | Lian Brian | CEO | Sell | 132,454 | $32.29 | $4.3M | SEC |
| Jan 5, 2026 | FOEHR MATTHEW W | Director | Sell | 16,000 | $35.11 | $562K | SEC |
In the last 12 months Viking Therapeutics, Inc. insiders made open-market purchases worth about $150,000 and sales worth about $22.3 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in VKTX was filed on 2026-07-29.
434 investment managers reported holding VKTX in SEC Form 13F filings for Q2 2026.
No congressional trades in VKTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).